Hepatitis B and hepatitis C are two distinct viral infections that attack the liver, causing inflammation that can lead to serious long-term damage. Despite sharing a name and a target organ, they are caused by different viruses, spread in different ways, and have very different treatment outlooks. Together, they affect over 300 million people worldwide: an estimated 254 million living with chronic hepatitis B and 50 million with chronic hepatitis C as of 2022.
Two Different Viruses, One Target
Hepatitis B is caused by a DNA virus, while hepatitis C is caused by an RNA virus. This distinction matters because it shapes how each virus behaves inside the body, how it replicates, and how well treatments can control or eliminate it. Both viruses specifically infect liver cells, triggering an immune response that causes inflammation. Over years or decades, that ongoing inflammation can scar the liver and impair its ability to filter toxins, produce proteins, and regulate metabolism.
The incubation period for hepatitis B, the time between exposure and the first signs of illness, averages about 90 days but can range from 60 to 150 days. Hepatitis C has a similar but slightly shorter window, typically 2 to 12 weeks after exposure. During this time, a person may have no idea they’ve been infected.
How Each Virus Spreads
Both viruses spread through contact with infected blood, but their other transmission routes differ in important ways.
Hepatitis B is highly contagious and can spread through blood, semen, and other body fluids. Sexual contact is a common route of transmission, as is sharing needles or syringes. A pregnant person with hepatitis B can also pass the virus to their baby during birth. The virus can survive outside the body for up to seven days, making it easier to transmit through everyday exposures like sharing razors or toothbrushes in a household with an infected person.
Hepatitis C spreads primarily through blood-to-blood contact. The most common route is sharing needles or other equipment used to inject drugs. Sexual transmission of hepatitis C is possible but much less efficient than with hepatitis B. Mother-to-child transmission also occurs but at lower rates. Hepatitis C does not spread through casual contact, sharing food, or breastfeeding.
Neither virus spreads through coughing, sneezing, hugging, or sharing utensils.
Symptoms Are Often Silent
One of the most dangerous features of both infections is that they frequently cause no symptoms at all, especially in the early stages. Many people carry either virus for years without knowing it, which is why screening is so important.
When symptoms do appear during an acute infection, they look similar for both viruses:
- Fatigue and loss of appetite
- Nausea, vomiting, or abdominal pain
- Dark urine or pale, clay-colored stools
- Yellowing of the skin and eyes (jaundice)
- Joint pain
- Fever
With hepatitis B, age plays a major role in whether symptoms show up. Most infants and children under 5 have no symptoms at all. Among people aged 5 and older, only 30% to 50% develop noticeable symptoms. Most people with chronic hepatitis B remain asymptomatic for decades, even as the virus quietly damages their liver. Chronic hepatitis C follows a similar pattern, often producing no symptoms until significant liver damage has already occurred.
Acute vs. Chronic Infection
Both infections start as acute, meaning short-term. The critical question is whether the body clears the virus on its own or whether the infection becomes chronic, meaning it persists for life.
With hepatitis B, age at infection is the strongest predictor. About 90% of infants infected at birth develop chronic hepatitis B, compared to roughly 5% of otherwise healthy adults. The adult immune system is usually able to fight off the virus completely within six months.
Hepatitis C is nearly the opposite. The majority of people who contract hepatitis C, roughly 55% to 85%, develop a chronic infection regardless of when they were infected. The immune system rarely clears this virus on its own. This is why hepatitis C is sometimes called a “silent epidemic”: most people who have it don’t know until the damage is advanced.
Long-Term Liver Damage
Chronic infection with either virus can lead to the same serious complications over time: progressive scarring of the liver (cirrhosis), liver failure, and liver cancer. The risk is real and well documented. Among people with hepatitis B-related cirrhosis, the five-year risk of developing liver cancer is roughly 10% in Western countries and up to 15% in regions where the virus is more common.
Hepatitis C follows a similar trajectory. About 15% to 30% of people with chronic hepatitis C develop cirrhosis over 20 to 30 years. Once cirrhosis is established, the risk of liver cancer increases substantially. Globally, viral hepatitis B and C together claim approximately 3,500 lives every day, mostly from these late-stage complications.
The speed of liver damage varies from person to person and depends on factors like alcohol use, body weight, coinfection with other viruses, and overall immune health. Some people with chronic hepatitis live for decades with minimal liver damage, while others progress to cirrhosis within 10 to 15 years.
Who Should Get Tested
Because both infections are so often symptom-free, routine screening is the only reliable way to catch them early.
The CDC recommends that all adults aged 18 and older be screened for hepatitis B at least once in their lifetime. People at higher ongoing risk should be tested periodically. This includes people who inject drugs or have a history of injection drug use, men who have sex with men, people born in regions where hepatitis B is common (prevalence of 2% or higher), people with HIV, household and sexual contacts of someone with hepatitis B, and people on dialysis. Pregnant women should be screened during every pregnancy, ideally in the first trimester.
For hepatitis C, the CDC recommends that all adults aged 18 and older get tested at least once, with a particular focus on people born between 1945 and 1965 (baby boomers), who account for a disproportionate share of chronic infections. Anyone who has ever injected drugs, even once, should be tested. Screening is a simple blood test, and anyone who requests testing should receive it regardless of whether they disclose specific risk factors.
Treatment: A Key Difference
This is where hepatitis B and C diverge most dramatically.
Hepatitis C is now curable. Antiviral medications taken by mouth for just 8 to 12 weeks cure the infection in more than 95% of cases. These treatments are well tolerated, with far fewer side effects than older therapies. A cure means the virus is completely eliminated from the body, though it doesn’t protect against reinfection. This represents one of the most significant advances in modern medicine: a chronic viral infection that can be fully eradicated with a short course of pills.
Hepatitis B, on the other hand, cannot currently be cured. Antiviral medications can suppress the virus and reduce liver damage, but they don’t eliminate it from the body. People who start treatment for chronic hepatitis B may need to take medication for the rest of their lives. Not everyone with chronic hepatitis B needs treatment right away. Doctors monitor liver function and viral activity to determine when the benefits of starting medication outweigh the commitment to lifelong therapy.
Prevention and Vaccination
A safe, highly effective vaccine exists for hepatitis B and has been available for decades. Multiple vaccines are approved, and studies show that immunity persists for at least 30 years when vaccination begins in infancy. The hepatitis B vaccine is part of the routine childhood immunization schedule in most countries, and it’s recommended for all unvaccinated adults. It’s one of the most successful vaccines ever developed and has dramatically reduced new infections in countries with high vaccination coverage.
No vaccine exists for hepatitis C. Prevention depends entirely on reducing exposure: avoiding shared needles, using barrier protection during sex when appropriate, and ensuring that tattoo or piercing equipment is properly sterilized. The good news is that even without a vaccine, the availability of a cure means that widespread testing and treatment could eventually bring hepatitis C under control.